Home › Bile Duct Cancer (Cholangiocarcinoma) › NCT06340646

Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

Who can join

Ages 18 and older · All sexes

Eligibility Criteria:

* Patients with cholangiocarcinoma, multiple myeloma, or early onset colon or rectal cancer.

  * If diagnosed with multiple myeloma, must be African-American.
  * If diagnosed with colon or rectal cancer, must be African-American AND must be no older than 65 years old at the time of diagnosis.
  * At least 18 years old
  * Able to understand and willing to sign an IRB-approved written informed consent document

About the study

The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches that direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research, and to investigate the impact of directly engaging participants in decisions regarding returning of genomic results on participants' health and satisfaction. Participants in this study will be presented with the choice of types of genomic results to receive, and the Engagement Optimization Unit (EOU) will investigate the impact of this intervention on participant knowledge, expectations of benefit, personal utility, and decisional conflict.

What is being tested

• Return of Genetic Results: Biomarker information from cancer cells (other)
• Return of Genetic Results: Inherited mutations related to cancer (other)
• Return of Genetic Results: Inherited mutations related to other medical issues (other)

Sponsor: Washington University School of Medicine · Participants: 990 · Started: Oct 18, 2022

Contact the study team

• Graham Colditz, M.D., DrPH, MPH · Phone: 314-454-7939
• Bettina Drake, Ph.D., MPH · Phone: 314-747-4534

Official record on ClinicalTrials.gov — NCT06340646

Locations in the U.S.

Conditions

• Bile Duct Cancer (Cholangiocarcinoma)
• Multiple Myeloma
• Colon Cancer
• Rectal Cancer
• Colorectal Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.